ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CLNN / news
HYFT (45) TLPH (36) PLRX (34) ONCY (41) ⌘ Pro Terminal →

Why CLNN Stock dropped -5.74% Today — RQD Quant Desk Flash

$3.61 -5.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.57

Clene Inc. (CLNN) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $54.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLNN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Clene Inc. (NASDAQ: CLNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $3.61 (-5.74% 1D, market cap $54.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CLNN ranks #912 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLNN compare to HYFT and TLPH in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLNN carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of -35.0%. By comparison, HYFT (MindWalk Holdings Corp.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $53.8M) and TLPH (Talphera Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $53.5M). Among the 5-stock peer group, CLNN leads on earnings multiple (N/A) while CLNN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLNN?
▼

Per CLNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822791), Clene Inc. generated $200.0K in revenue (-41.5% YoY), -$26.2M in net income, and -$18.6M in free cash flow against $18.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.57 (-1.22%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510026
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (6)Whales (5)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.4% Base Target
$14 Bull$3 Base$2 Bear
📬 FREE CLNN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLNN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY CLNN SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 49.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 15.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$3.68-10.6% Next Q
Q2 (-2Q)
31
Grade E$3.29+16.7% Next Q
Q3 (-1Q)
29
Grade E$3.84-6% Next Q
Current
26
Grade E$3.61-10.5% Hist 90D α
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLNN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLNN currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.94) and Max Pain ($3.79) forces dealer call-delta covering toward $14.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why CLNN Stock dropped -5.74% Today — RQD Quant Desk Flash

Clene Inc. (CLNN) dropped -5.74% to $3.61, trading at 6% of its 52-week range ($3.02 – $13.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 6% of its 52-week range ($3.02 – $13.5) with RSI-14 at 49.4 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.61 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 15.7% gross margin and $0 annual free cash flow.
Live CLNN Headlines & Catalysts
MARKET WIREBenzinga • 14d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLNN)

  • ✓Walkthrough of CLNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.38%⚡ TESTING RESISTANCE
2026-11-03O $3.90H $3.90L $3.61C $3.61VOL 47.3K
RES: $3.97SUP: $2.21SMA50: $3.94SMA200: $5.18
$9.07$7.43$5.79$4.15$2.51RES $3.97SUP $2.21$3.612026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLNN Butterfly Map → + Track CLNN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -41.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLNN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLNN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLNN)

Health Care Rank #912 of 1015 ⚔️ HYFT vs CLNN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLNN vs. HYFT, TLPH, PLRX, ONCY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Clene Inc. (CLNN) ranks #912 by composite RQD confidence (26/100, grade E) and #728 by equity capitalization ($54.4M). Within this direct 5-issuer industry benchmark cohort, CLNN leads on earnings valuation at N/A trailing P/E, while CLNN leads on capital efficiency and profitability with -35.0% ROIC and 78.5% gross margin. HYFT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with CLNN at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLNN ACTIVE
Clene Inc.
E 26/100 — 78.5% -35.0% -5.74% $54.4M Benchmark Subject
HYFT
MindWalk Holdings Corp.
D 45/100 — — — -2.65% $53.8M /hyft-vs-clnn →
TLPH
Talphera Inc.
D- 36/100 — — -35.0% -1.94% $53.5M /tlph-vs-clnn →
PLRX
Pliant Therapeutics Inc.
E 34/100 — — -35.0% -2.29% $53.2M /plrx-vs-clnn →
ONCY
Oncolytics Biotech Inc.
D- 41/100 — — -35.0% -5.97% $55.8M /oncy-vs-clnn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001822791 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Clene Inc. (CLNN) reported GAAP revenue of $200.0K (-41.5% vs. FY2024 revenue of $342.0K , and -69.4% cumulative change since FY2023) , GAAP net income of -$26.2M, operating cash flow of -$18.5M, and free cash flow of -$18.6M (+12.9% YoY). On the balance sheet, CLNN closed FY2025 with $18.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $200.0K -$26.2M -$18.5M -$18.6M $18.1M —
FY2024 (FY) 2024-12-31 $342.0K -$39.4M -$21.3M -$21.3M $27.3M —
FY2023 (FY) 2023-12-31 $654.0K -$49.5M -$30.2M -$30.2M — —

3. CLNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Clene Inc. (NASDAQ: CLNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $3.61 (-5.74% 1D, market cap $54.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CLNN ranks #912 in composite RQD confidence.

How does CLNN compare to HYFT and TLPH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLNN carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of -35.0%. By comparison, HYFT (MindWalk Holdings Corp.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $53.8M) and TLPH (Talphera Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $53.5M). Among the 5-stock peer group, CLNN leads on earnings multiple (N/A) while CLNN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLNN?

Per CLNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822791), Clene Inc. generated $200.0K in revenue (-41.5% YoY), -$26.2M in net income, and -$18.6M in free cash flow against $18.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLNN trading relative to its 50-day, 200-day, and 52-week technical levels?

CLNN last traded at $3.61 (-5.74% on volume of 54,019 shares), positioning the stock -8.38% below its 50-day simple moving average ($3.94) and -30.31% below its 200-day simple moving average ($5.18). Across its 52-week range of $3.02 to $13.50, CLNN sits at the 5.6% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.16 to $4.06).

Direct Sub-Reports: CLNN RQD Cockpit CLNN 12M Forecast CLNN Earnings & Move CLNN Dividends & DRIP CLNN Insiders & 13F CLNN Whale Options CLNN Profit Sankey CLNN News & Why
ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

CLNN — Clene Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Clene Inc. (CLNN) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.61 (-5.74% 1D, market capitalization $54.4M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 78.5%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Clene Inc. (CLNN) is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Reported revenue is small, at $0.2M for FY 2025. Per the news wire, the company has an application seeking accelerated approval for an ALS drug, submitted in October.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Clene Inc. (CLNN) reported $200.0K in annual revenue (up from $342.0K in FY2024, -41.5% YoY) and -$26.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($654.0K revenue, -$49.5M net income) through FY2025, CLNN scaled operating cash flow to -$18.5M and free cash flow to -$18.6M, backed by $18.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $3.02 – $13.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level fact available is the Health Care / Pharmaceutical Preparations classification. A prospective investor should watch whether the ALS accelerated-approval application advances, since regulatory outcome is the most direct 2nd-order driver evident in the news wire.

  • Key Question #1: Can CLNN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $200.0K and free cash flow of -$18.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CLNN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLNN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Clene Inc. (CLNN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLNN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLNN Bull vs. Bear Conversation Board — What's Your Call at $3.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLNN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CLNN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $4.52 (+18.0%)
📌 Pinned Debate

The ALS drug accelerated-approval application submitted in October is a potential regulatory catalyst that could re-rate a stock tradin

Here is why I am bullish on CLNN here at $3.83: The ALS drug accelerated-approval application submitted in October is a potential regulatory catalyst that could re-rate a stock trading 72% below its 52-week high.. Compare CLNN's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $3.64 are getting bought.

ArenaChamp_24 🐂 BULL

@DeltaGamma_99 Agree on the RQD 26/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.83 and keeping dry powder in case we test $3.56.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.18 (-17.0%)
Spot @ $3.83

With ROIC at -35%, FCF yield at 0%, a 3/20 insider-conviction pillar, and cash falling to $5.2M, the company shows weak cash generation

Careful chasing CLNN at $3.83. With ROIC at -35%, FCF yield at 0%, a 3/20 insider-conviction pillar, and cash falling to $5.2M, the company shows weak cash generation and limited balance-sheet cushion.. Gross margin is 78.5%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.18 on multiple compression.

LIVE TAPE